Effect of hyperthermic intraperitoneal chemotherapy on patients with advanced colorectal cancer: a systematic review and meta-analysis.
메타분석
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
2851 patients.
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
Further investigation is required to clarify the role of HIPEC in more high-quality RCTs. [SUPPLEMENTARY INFORMATION] The online version contains supplementary material available at 10.1186/s12957-025-04165-7.
[BACKGROUND] Advanced colorectal cancer (CRC) predisposes to peritoneal metastases (PM), leading to a decreased survival rate.
- OR 1.49
APA
Su Z, Guo Y, et al. (2026). Effect of hyperthermic intraperitoneal chemotherapy on patients with advanced colorectal cancer: a systematic review and meta-analysis.. World journal of surgical oncology, 24(1). https://doi.org/10.1186/s12957-025-04165-7
MLA
Su Z, et al.. "Effect of hyperthermic intraperitoneal chemotherapy on patients with advanced colorectal cancer: a systematic review and meta-analysis.." World journal of surgical oncology, vol. 24, no. 1, 2026.
PMID
41612371
Abstract
[BACKGROUND] Advanced colorectal cancer (CRC) predisposes to peritoneal metastases (PM), leading to a decreased survival rate. Advanced CRC includes CRC with PM (CRC-PM) and locally advanced high-risk CRC without PM. The effectiveness of hyperthermic intraperitoneal chemotherapy (HIPEC) in prolonging survival and in treating or preventing PM after surgery for advanced CRC is still uncertain.
[METHODS] A search of PubMed, Cochrane, Embase, and Web of science databases for relevant studies prior to April 2024 was performed. Data were analyzed using Stata/MP 17.0 software. The primary outcomes included overall survival (OS) and disease-free survival (DFS). Secondary outcomes were overall recurrence rate (ORR), PM rate, and complications. The quality of evidence was assessed using Grading of Recommendations, Assessment, Development, and Evaluations (GRADE).
[RESULTS] A total of ten high-quality cohort studies and four randomized controlled trials (RCTs) were included, encompassing 2851 patients. HIPEC improved 1-year DFS (odds ratio (OR) = 1.64, 95%Cl: 1.09–2.46) and 5-year OS (OR = 1.49, 95%Cl: 1.10–2.03) in advanced CRC. HIPEC also reduced the overall PM rate (OR = 0.66, 95%Cl: 0.49–0.90). For advanced high-risk CRC without prior PM, HIPEC reduced the PM rate and had a preventive effect (OR = 0.71, 95%Cl: 0.52–0.97). In terms of complications, HIPEC increased the incidence of thrombopenia (OR = 5.77, 95%Cl: 1.65–20.09) and neutropenia (OR = 3.21, 95%Cl: 1.74–5.90). The quality of evidence ranged from high to very low.
[CONCLUSION] The use of HIPEC in treating advanced CRC may result in improved survival rates and a reduction in peritoneal recurrence or metastasis, although complications should be considered. Further investigation is required to clarify the role of HIPEC in more high-quality RCTs.
[SUPPLEMENTARY INFORMATION] The online version contains supplementary material available at 10.1186/s12957-025-04165-7.
[METHODS] A search of PubMed, Cochrane, Embase, and Web of science databases for relevant studies prior to April 2024 was performed. Data were analyzed using Stata/MP 17.0 software. The primary outcomes included overall survival (OS) and disease-free survival (DFS). Secondary outcomes were overall recurrence rate (ORR), PM rate, and complications. The quality of evidence was assessed using Grading of Recommendations, Assessment, Development, and Evaluations (GRADE).
[RESULTS] A total of ten high-quality cohort studies and four randomized controlled trials (RCTs) were included, encompassing 2851 patients. HIPEC improved 1-year DFS (odds ratio (OR) = 1.64, 95%Cl: 1.09–2.46) and 5-year OS (OR = 1.49, 95%Cl: 1.10–2.03) in advanced CRC. HIPEC also reduced the overall PM rate (OR = 0.66, 95%Cl: 0.49–0.90). For advanced high-risk CRC without prior PM, HIPEC reduced the PM rate and had a preventive effect (OR = 0.71, 95%Cl: 0.52–0.97). In terms of complications, HIPEC increased the incidence of thrombopenia (OR = 5.77, 95%Cl: 1.65–20.09) and neutropenia (OR = 3.21, 95%Cl: 1.74–5.90). The quality of evidence ranged from high to very low.
[CONCLUSION] The use of HIPEC in treating advanced CRC may result in improved survival rates and a reduction in peritoneal recurrence or metastasis, although complications should be considered. Further investigation is required to clarify the role of HIPEC in more high-quality RCTs.
[SUPPLEMENTARY INFORMATION] The online version contains supplementary material available at 10.1186/s12957-025-04165-7.
같은 제1저자의 인용 많은 논문 (5)
- Comment on "Acute Promyelocytic Leukemia with other rearrangements".
- Unveiling personalised targets of PD-1 blockade hyperprogression in a cervical adenocarcinoma via longitudinal single-cell and spatial monitoring.
- Concurrent chronic myelomonocytic leukemia and monoclonal gammopathy: Case report and literature review.
- CSF3R T618I Mutated Chronic Myelomonocytic Leukemia Accompanied by Ankylosing Spondylitis.
- Clinical efficacy of 2-week and 3-week albumin-bound paclitaxel therapy for advanced pancreatic cancer.